Pfizer Takes J&J To Court As Analysts Shake Up Pharma Ratings

Morgan Stanley analyst David Risinger upgraded Pfizer this morning to Overweight, a Buy-equivalent rating, as he believes investors underappreciate the global prospects for breast cancer drug Ibrance.